It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Uveitis is characterised by breakdown of the blood-retinal barrier (BRB), allowing infiltration of immune cells that mediate intraocular inflammation, which can lead to irreversible damage of the neuroretina and the loss of sight. Treatment of uveitis relies heavily on corticosteroids and systemic immunosuppression due to limited understanding of disease pathogenesis. We performed single-cell RNA-sequencing of retinas, as well as bulk RNA-sequencing of retinal pigment epithelial (RPE) cells from mice with experimental autoimmune uveitis (EAU) versus healthy control. This revealed that the Th1/Th17-driven disease induced strong gene expression changes in response to inflammation in rods, cones, Müller glia and RPE. In particular, Müller glia and RPE cells were found to upregulate expression of chemokines, complement factors, leukocyte adhesion molecules and MHC class II, thus highlighting their contributions to immune cell recruitment and antigen presentation at the inner and outer BRB, respectively. Additionally, ligand-receptor interaction analysis with CellPhoneDB revealed key interactions between Müller glia and T cell / natural killer cell subsets via chemokines, galectin-9 to P4HB/TIM-3, PD-L1 to PD-1, and nectin-2/3 to TIGIT signalling axes. Our findings elucidate mechanisms contributing to breakdown of retinal immune privilege during uveitis and identify novel targets for therapeutic interventions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Oxford, Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
2 MiroBio Ltd, Oxford, UK (GRID:grid.4991.5); John Radcliffe Hospital, University of Oxford, Radcliffe Department of Medicine, Oxford, UK (GRID:grid.8348.7) (ISNI:0000 0001 2306 7492); John Radcliffe Hospital, University of Oxford, Medical Research Council Human Immunology Unit, Oxford, UK (GRID:grid.8348.7) (ISNI:0000 0001 2306 7492)
3 MiroBio Ltd, Oxford, UK (GRID:grid.8348.7)
4 University of Oxford, Respiratory Medicine Unit, Nuffield Department of Medicine, Experimental Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
5 John Radcliffe Hospital, University of Oxford, Radcliffe Department of Medicine, Oxford, UK (GRID:grid.8348.7) (ISNI:0000 0001 2306 7492); John Radcliffe Hospital, University of Oxford, Medical Research Council Human Immunology Unit, Oxford, UK (GRID:grid.8348.7) (ISNI:0000 0001 2306 7492)
6 University of Oxford, Nuffield Department of Medicine, Henry Wellcome Building for Molecular Physiology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); CAMS Oxford Institute, University of Oxford, Henry Wellcome Building for Molecular Physiology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
7 University of Oxford, Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (GRID:grid.8348.7) (ISNI:0000 0001 2306 7492)
8 University of Oxford, Nuffield Department of Medicine, Wellcome Centre for Human Genetics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Kennedy Institute of Rheumatology, University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
9 University of Oxford, Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (GRID:grid.8348.7) (ISNI:0000 0001 2306 7492); John Radcliffe Hospital, Nuffield Department of Clinical Neurosciences, Oxford, UK (GRID:grid.8348.7) (ISNI:0000 0001 2306 7492)